Eterna therapeutics inc.ERNA.US Overview
ERNA Overall Performance
ERNA AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
ERNA Current Performance
-1.32%
Eterna therapeutics inc.
2.97%
Avg of Sector
1.52%
S&P500
ERNA Key Information
ERNA Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
ERNA Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
ERNA Profile
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
Price of ERNA
ERNA FAQ
When is ERNA's latest earnings report released?
The most recent financial report for Eterna therapeutics inc. (ERNA) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ERNA's short-term business performance and financial health. For the latest updates on ERNA's earnings releases, visit this page regularly.
How is ERNA's revenue growth?
In the latest financial report, Eterna therapeutics inc. (ERNA) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ERNA have?
As of the end of the reporting period, Eterna therapeutics inc. (ERNA) had total debt of 593K, with a debt ratio of 0.08. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ERNA have?
At the end of the period, Eterna therapeutics inc. (ERNA) held Total Cash and Cash Equivalents of 4.32M, accounting for 0.57 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is ERNA's EPS continuing to grow?
According to the past four quarterly reports, Eterna therapeutics inc. (ERNA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.61. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ERNA?
Eterna therapeutics inc. (ERNA)'s Free Cash Flow (FCF) for the period is -2.53M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 0.96% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of ERNA?
The latest valuation data shows Eterna therapeutics inc. (ERNA) has a Price-To-Earnings (PE) ratio of -0.29 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.